» Articles » PMID: 30405616

in Chronic Lung Infections: How to Adapt Within the Host?

Overview
Journal Front Immunol
Date 2018 Nov 9
PMID 30405616
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteria that readily adapt to different natural environments, can also exploit this versatility upon infection of the host to persist. , a ubiquitous Gram-negative bacterium, is harmless to healthy individuals, and yet a formidable opportunistic pathogen in compromised hosts. When pathogenic, causes invasive and highly lethal disease in certain compromised hosts. In others, such as individuals with the genetic disease cystic fibrosis, this pathogen causes chronic lung infections which persist for decades. During chronic lung infections, adapts to the host environment by evolving toward a state of reduced bacterial invasiveness that favors bacterial persistence without causing overwhelming host injury. Host responses to chronic infections are complex and dynamic, ranging from vigorous activation of innate immune responses that are ineffective at eradicating the infecting bacteria, to relative host tolerance and dampened activation of host immunity. This review will examine how subverts host defenses and modulates immune and inflammatory responses during chronic infection. This dynamic interplay between host and pathogen is a major determinant in the pathogenesis of chronic lung infections.

Citing Articles

R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa.

Mei M, Estrada I, Diggle S, Goldberg J NPJ Antimicrob Resist. 2025; 3(1):17.

PMID: 40021925 PMC: 11871291. DOI: 10.1038/s44259-025-00088-1.


DJK-5, an anti-biofilm peptide, increases Staphylococcus aureus sensitivity to colistin killing in co-biofilms with Pseudomonas aeruginosa.

Wardell S, Yung D, Gupta A, Bostina M, Overhage J, Hancock R NPJ Biofilms Microbiomes. 2025; 11(1):8.

PMID: 39779734 PMC: 11711674. DOI: 10.1038/s41522-024-00637-y.


Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial Biofilms.

Roque-Borda C, Primo L, Medina-Alarcon K, Campos I, de Fatima Nascimento C, Saraiva M Adv Sci (Weinh). 2024; 12(1):e2410893.

PMID: 39530703 PMC: 11714181. DOI: 10.1002/advs.202410893.


Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.

Alqasmi M J Clin Med. 2024; 13(21).

PMID: 39518670 PMC: 11547045. DOI: 10.3390/jcm13216530.


AFM41a: A Novel PAD2 Inhibitor for Sepsis Treatment-Efficacy and Mechanism.

Dong T, Barasa L, Yu X, Ouyang W, Shao L, Quan C Int J Biol Sci. 2024; 20(13):5043-5055.

PMID: 39430255 PMC: 11488583. DOI: 10.7150/ijbs.97166.


References
1.
Iannitti R, Napolioni V, Oikonomou V, De Luca A, Galosi C, Pariano M . IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun. 2016; 7:10791. PMC: 4793079. DOI: 10.1038/ncomms10791. View

2.
Horvat R, Clabaugh M, Parmely M . Inactivation of human gamma interferon by Pseudomonas aeruginosa proteases: elastase augments the effects of alkaline protease despite the presence of alpha 2-macroglobulin. Infect Immun. 1989; 57(6):1668-74. PMC: 313337. DOI: 10.1128/iai.57.6.1668-1674.1989. View

3.
Tart A, Blanks M, Wozniak D . The AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, nonmotile Pseudomonas aeruginosa cystic fibrosis isolates. J Bacteriol. 2006; 188(18):6483-9. PMC: 1595476. DOI: 10.1128/JB.00636-06. View

4.
Yang J, Zhao Y, Shi J, Shao F . Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A. 2013; 110(35):14408-13. PMC: 3761597. DOI: 10.1073/pnas.1306376110. View

5.
Ratner D, Mueller C . Immune responses in cystic fibrosis: are they intrinsically defective?. Am J Respir Cell Mol Biol. 2012; 46(6):715-22. DOI: 10.1165/rcmb.2011-0399RT. View